Stocktoria
Opus Genetics, Inc. IRD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2004-11-30
Opus Genetics, Inc. insider transactions (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | director | 2026-05-18 | Sell | 1,700,000 | $4.35 |
| YERXA BENJAMIN R | President | 2026-04-23 | Sell | 7,470 | $5.24 |
| SCHACHLE JOSEPH K | Chief Operating Officer | 2026-04-23 | Sell | 4,697 | $5.22 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance | 2026-04-23 | Sell | 1,641 | $5.20 |
| Magrath George | Chief Executive Officer | 2026-04-23 | Sell | 9,511 | $5.22 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | 2026-04-23 | Sell | 7,542 | $5.19 |
| Gagnon Robert E. | Chief Financial Officer | 2026-04-23 | Sell | 7,842 | $5.18 |
| Rodgers Richard J | director | 2026-04-20 | Grant | 24,367 | — |
Source: SEC EDGAR filings · CIK 0001228627 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.